Advertisement

Topics

Latest "Reddy Laboratories" News Stories

13:40 EDT 23rd July 2018 | BioPortfolio

Here are the most relevant search results for "Reddy Laboratories" found in our extensive news archives from over 250 global news sources.

More Information about Reddy Laboratories on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Reddy Laboratories for you to read. Along with our medical data and news we also list Reddy Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of Reddy Laboratories Companies for you to search.

Showing "Reddy Laboratories" News Articles 1–25 of 1,800+

Extremely Relevant

Dr. Reddy's Launches Levocetirizine Dihydrochloride Tablets In U.S. Market

NewsDr. Reddy’s Laboratories has launched an over-the-counter therapeutic equivalent generic version of Xyzal Allergy 24HR Tablets in the United States market.


Deals this week: Dr. Reddy’s Laboratories, Pluristem Therapeutics, Fortress Biotech

Dr. Reddy’s Laboratories has signed a distribution agreement with UCB to supply the latter’s epilepsy drug Briviact in India. As...Read More... The post Deals this week: Dr. Reddy’s Laboratories, Pluristem Therapeutics, Fortress Biotech appeared first on Pharmaceutical Technology.

FDA Approves First Generic Version Of Suboxone

NewsDr. Reddy's Laboratories announces final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. market.


Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary ...

Dr. Reddy’s Laboratories Ltd.INVESTOR RELATIONSSAUNAK SAVLA, +91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN PRINTER, +91-40-49002121calvinprinter@drreddys.com Read more...

Dr Reddy's receives FDA 483 at Indian API plant

The US FDA has issued a Form 483 with four observations to an API facility in Hyderabad, India run by Dr Reddyâs Laboratories.

Dr. Reddy’s Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court for the District … Continue reading → Cet article Dr. Reddy’s Laboratories defends its right to lau...

BRIEF—Dr Reddy’s files NDA for its migraine candidate

India’s Dr Reddy’s Laboratories has announced the filing of New Drug Application (NDA) for its migraine…

US FDA clears troubled API plants following two Form 483s, says Dr. Reddy’s

Dr. Reddyâs Laboratories has announced receipt of a US FDA establishment inspection report regarding two active pharmaceutical ingredient plants in Hyderabad, India.

Court fines Dr Reddy’s for improperly packaging products

On 18 December 2017, the District of New Jersey filed a complaint against Dr. Reddy’s Laboratories for failing to comply with the Poison Prevention Packaging Act (PPPA) and the Consumer Product Safety Act (CPSA). Just over a month later, the district court handed down a $5 million penalty and entered a permanent injunction to prevent Dr. Reddy’s from distributing prescription drugs not in chi...

Dr. Reddy’s Laboratories Announces FDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent …

Dr. Reddy's granted Indian rights to epilepsy therapy

UCB has granted Dr. Reddy's Laboratories exclusive rights to market Briviact, or brivaracetam, in India.  -More- 

Relevant

Dr. Reddy’s recalling 236,000 bottles of statins from US

The US FDA has announced that over 236,000 bottles of statins will be voluntarily recalled by Dr. Reddyâs Laboratories, after issues were found with impurities.

Dr. Reddy's Launches Generic Version Of Nexium 24HR Capsules

NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter therapeutic equivalent generic ver...

US court issues a restraint order against Dr Reddy’s new drug

Indian pharmaceutical company Dr Reddy’s Laboratories has announced that the US District Court in New Jersey has issued a temporary restraining...Read More... The post US court issues a restraint order against Dr Reddy’s new drug appeared first on Pharmaceutical Technology.

Dr Reddy's Labs' sales and profit under pressure in Q4, dividend at 400%

Dr Reddy's Laboratories (DRL), a Rs. 14,200 crore plus pharma major, has suffered another setback during the fourth quarter ended March 2018 on account of stagnant sales, significant higher tax provisions, price erosion

Indivior seeks injunction to block Dr. Reddy’s generic launch in US

Indivior has requested a temporary restraining order against Dr. Reddyâs Laboratories to prevent further sales of its generic buprenorphine and naloxone sublingual film product in the US.

Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 18022018] Prices from USD $350

Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Dr. Reddy's Laboratories Limited Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership tra...

Dr. Reddy’s Files NDA for Migraine Treatment

Migraine sufferers could have a new treatment option. India-based Dr. Reddy’s Laboratories and its subsidiary Promius Pharma, LLC filed a NDA with the U.S. FDA for approval of migraine candidate DFN-02.

Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration

Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and...   

Active-Investors: Blog Exposure - Dr. Reddy's Launches its Levocetirizine Dihydrochloride Tablets in the US Market

Stock Monitor: Amphastar Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Dr. Reddy's Laboratories Ltd (NYS...

Dr. Reddy’s, Mylan Secure Approval for Suboxone Generic, Shares of Indivior Fall on the News

Shares of Dr. Reddy’s Laboratories Ltd. are surging this morning after the FDA approved its generic version of Suboxone (buprenorphine and naloxone) sublingual film for opioid addiction.

Dr Reddy’s Pins Hopes On Complex Drugs Pipeline Amid Weak Q3

Dr Reddy’s Laboratories is betting on complex product launches to power an improvement in its bottom line after reporting a...   

Dr Reddy’s hit by yet another recall, of 80,000+ bottles

Dr Reddy’s Laboratories problem with ensuring products reach the market at a quality the FDA deems acceptable is no secret and, unfortunately for the company, it has once again been slapped with a recall of over 80,000 bottles of Atorvastatin. Only last month, it was forced to recall more than 1,000 Docetaxel injection vials used to treat breast cancer and was also hit by a fine for improperly p...

Indivior wins US court order blocking Dr. Reddy's sale of generic opioid treatment

A US court has approved Indivior’s preliminary injunction (PI) preventing Dr. Reddy's Laboratories (DRL) from marketing of generic opioid addiction treatment.

US court prevents Dr. Reddy's from marketing generic opioid treatment

A US court has approved Indivior’s preliminary injunction (IP) preventing India-based Dr. Reddy's Laboratories (DRL) from marketing of generic opioid addiction treatment.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks